EpiPen Price Increases, Part 1 Following a break for lawmakers to cast votes on the House floor, Mylan, Inc. CEO Heather Bresch continued testifying before the House Oversight and… read more
EpiPen Price Increases, Part 1 Following a break for lawmakers to cast votes on the House floor, Mylan, Inc. CEO Heather Bresch continued testifying before the House Oversight and Government Reform Committee on her company’s price increase on its anti-anaphylaxis injection medication known as the EpiPen. Lawmakers from both parties questioned Ms. Bresch on the reasons for the price increase, which totaled more than 500 percent over a seven-year period. She defended the price increases, saying the company has boosted EpiPen’s availability to consumers of all means, and to public schools. close
Javascript must be enabled in order to access C-SPAN videos.
*This transcript was compiled from uncorrected Closed Captioning.